ABSTRACT
Cervical mucus and ultrasonic ovearian follicle monitoring for individualization of urinary follicle-stimualting hormone [ufsh] and human menopausal gonadotropin [hmg] therapy were used in clomiphene citrate resistant patients of polycystic ovarin disease [PCOD]. This study was carried out on 17 patients with PCOD, they were divided into group I : consisted of 7 patients receiving ufsh and group II: consisted of 10 patients receiving hmg. Cervical score and pelvic scanning for each patient were done daily. In this trial, the number of cycles in group I and II were 8 and 18 respectively. Ovulation and cycle fecundity were higher with hMG therapy than ufsh. This study revealed that low dose ufsh and hmg are effective in preventing the occurrence of hyperstimulation syndrome. Also, pelvic ultrasound is essential for follicular scanning and detection of ovulation while the cervical mucus score had a limited role in that aspect. Also, we conclude that hmg is more effective than ufsh in treating comiphene resistant PCOD